[x]
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
[ ]
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
British Columbia, Canada
|
980597776
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(I.R.S. Employer
Identification No.)
|
100-8900 Glenlyon Parkway, Burnaby, BC, Canada
|
V5J 5J8
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer [ ]
|
Accelerated filer [ ]
|
Non-accelerated filer [x]
(Do not check if a smaller reporting company)
|
Smaller reporting company [ ]
|
Page
|
|
ITEM 1.
|
FINANCIAL STATEMENTS (Unaudited)
|
March 31
2014
|
December 31
2013
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 134,357 | $ | 68,717 | ||||
Accounts receivable
|
1,521 | 117 | ||||||
Accrued revenue
|
412 | 212 | ||||||
Deferred expenses
|
111 | 173 | ||||||
Investment tax credits receivable
|
39 | 40 | ||||||
Prepaid expenses and other assets
|
561 | 1,084 | ||||||
Total current assets
|
137,001 | 70,343 | ||||||
Property and equipment
|
13,367 | 13,039 | ||||||
Less accumulated depreciation
|
(11,846 | ) | (11,666 | ) | ||||
Property and equipment, net of accumulated depreciation
|
1,521 | 1,373 | ||||||
Total assets
|
$ | 138,522 | $ | 71,716 | ||||
Liabilities and stockholders' equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities (note 4)
|
$ | 4,594 | $ | 3,680 | ||||
Deferred revenue (note 3)
|
5,621 | 3,463 | ||||||
Warrants (note 2)
|
12,824 | 5,379 | ||||||
Total current liabilities
|
23,039 | 12,522 | ||||||
Deferred revenue, net of current portion (note 3)
|
10,000 | - | ||||||
Total liabilities
|
33,039 | 12,522 | ||||||
Stockholders’ equity:
|
||||||||
Common shares (note 5) Authorized - unlimited number with no par value
|
||||||||
Issued and outstanding: 21,992,088 (December 31, 2013 - 19,048,900)
|
283,640 | 216,702 | ||||||
Additional paid-in capital
|
24,837 | 25,343 | ||||||
Deficit
|
(185,011 | ) | (167,027 | ) | ||||
Accumulated other comprehensive income (loss)
|
(17,983 | ) | (15,824 | ) | ||||
Total stockholders' equity
|
105,483 | 59,194 | ||||||
Total liabilities and stockholders' equity
|
$ | 138,522 | $ | 71,716 |
Three months ended
March 31
|
||||||||
2014
|
2013
|
|||||||
Revenue (note 3)
|
||||||||
Collaborations and contracts
|
$ | 3,689 | $ | 2,132 | ||||
Licensing fees, milestone and royalty payments
|
741 | - | ||||||
Total revenue
|
4,430 | 2,132 | ||||||
Expenses
|
||||||||
Research, development, collaborations and contracts
|
8,204 | 4,067 | ||||||
General and administrative
|
2,050 | 893 | ||||||
Depreciation of property and equipment
|
134 | 166 | ||||||
Total expenses
|
$ | 10,388 | $ | 5,126 | ||||
Loss from operations
|
(5,958 | ) | (2,994 | ) | ||||
Other income (losses)
|
||||||||
Interest income
|
147 | 145 | ||||||
Foreign exchange gains (losses)
|
1,443 | (5 | ) | |||||
(Increase) decrease in fair value of warrant liability
|
(13,616 | ) | 308 | |||||
Net loss
|
$ | (17,984 | ) | $ | (2,546 | ) | ||
Income (loss) per common share
|
||||||||
Basic and diluted
|
$ | (0.91 | ) | $ | (0.18 | ) | ||
Weighted average number of common shares
|
||||||||
Basic and diluted
|
19,801,428 | 14,344,152 | ||||||
Comprehensive loss
|
||||||||
Cumulative translation adjustment
|
(2,159 | ) | (876 | ) | ||||
Comprehensive loss
|
$ | (20,143 | ) | $ | (3,422 | ) |
Number
of shares
|
Share
capital
|
Additional paid-in
capital
|
Deficit
|
Accumulated
other
comprehensive
loss
|
Total
stockholders'
equity
|
|||||||||||||||||||
Balance, December 31, 2013
|
19,048,900 | $ | 216,702 | $ | 25,343 | $ | (167,027 | ) | $ | (15,824 | ) | $ | 59,194 | |||||||||||
Stock-based compensation
|
- | - | 1,188 | - | - | 1,188 | ||||||||||||||||||
Issuance of common shares pursuant to exercise of options
|
475,210 | 3,618 | (1,694 | ) | - | - | 1,924 | |||||||||||||||||
|
||||||||||||||||||||||||
Issuance of common shares pursuant to exercise of warrants
|
342,978 | 6,843 | - | - | - | 6,843 | ||||||||||||||||||
Issuance of common shares in conjunction with the private offering, net of issuance costs of $4,085,000
|
2,125,000 | 56,477 | - | - | - | 56,477 | ||||||||||||||||||
Currency translation adjustment
|
- | - | - | - | (2,159 | ) | (2,159 | ) | ||||||||||||||||
Net loss
|
- | - | - | (17,984 | ) | - | (17,984 | ) | ||||||||||||||||
Balance, March 31, 2014
|
21,992,088 | $ | 283,640 | $ | 24,837 | $ | (185,011 | ) | $ | (17,983 | ) | $ | 105,483 |
Three months ended
March 31
|
||||||||
2014
|
2013
|
|||||||
OPERATING ACTIVITIES
|
||||||||
Loss for the period
|
$ | (17,984 | ) | $ | (2,546 | ) | ||
Items not involving cash:
|
||||||||
Depreciation of property and equipment
|
134 | 166 | ||||||
Stock-based compensation - research, development, collaborations and contract expenses
|
848 | 103 | ||||||
Stock-based compensation - general and administrative expenses
|
340 | 28 | ||||||
Unrealized foreign exchange (gains) losses
|
(59 | ) | 6 | |||||
Warrant issuance costs
|
||||||||
Change in fair value of warrant liability
|
13,616 | (308 | ) | |||||
Net change in non-cash operating items:
|
||||||||
Accounts receivable
|
(1,409 | ) | (417 | ) | ||||
Accrued revenue
|
(208 | ) | (1,106 | ) | ||||
Deferred expenses
|
55 | 60 | ||||||
Prepaid expenses and other assets
|
482 | (494 | ) | |||||
Accounts payable and accrued liabilities
|
1,051 | 807 | ||||||
Deferred revenue
|
12,289 | 861 | ||||||
Net cash provided by (used in) operating activities
|
9,155 | (2,840 | ) | |||||
INVESTING ACTIVITIES
|
||||||||
Acquisition of property and equipment
|
(335 | ) | (201 | ) | ||||
Net cash used in investing activities
|
(335 | ) | (201 | ) | ||||
FINANCING ACTIVITIES
|
||||||||
Proceeds from issuance of common shares, net of issuance costs
|
56,477 | - | ||||||
Issuance of common shares pursuant to exercise of options
|
1,924 | 82 | ||||||
Issuance of common shares pursuant to exercise of warrants
|
888 | 56 | ||||||
Net cash provided by financing activities
|
59,289 | 138 | ||||||
Effect of foreign exchange rate changes on cash & cash equivalents
|
(2,469 | ) | (999 | ) | ||||
Increase (decrease) in cash and cash equivalents
|
65,640 | (3,902 | ) | |||||
Cash and cash equivalents, beginning of period
|
68,717 | 47,024 | ||||||
Cash and cash equivalents, end of period
|
$ | 134,357 | $ | 43,122 | ||||
Supplemental cash flow information
|
||||||||
Fair value of warrants exercised on a cashless basis
|
$ | - | $ | 107 |
1.
|
Nature of business and future operations
|
2.
|
Significant accounting policies
|
•
|
Level 1 inputs are quoted market prices for identical instruments available in active markets.
|
•
|
Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.
|
•
|
Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.
|
Level 1
|
Level 2
|
Level 3
|
March 31, 2014
|
|||||||||||||
Assets
|
||||||||||||||||
Cash
|
$ | 134,357 | - | - | $ | 134,357 | ||||||||||
Liabilities
|
||||||||||||||||
Warrants
|
- | - | $ | 12,824 | $ | 12,824 | ||||||||||
Financial Instrument
|
- | - | 0 | 0 | ||||||||||||
Total
|
- | - | $ | 12,824 | $ | 12,824 |
Level 1
|
Level 2
|
Level 3
|
December 31, 2013
|
|||||||||||||
Assets
|
||||||||||||||||
Cash
|
$ | 68,717 | - | - | $ | 68,717 | ||||||||||
Liabilities
|
||||||||||||||||
Warrants
|
- | - | $ | 5,379 | $ | 5,379 |
Liability at beginning of the period
|
Opening liability of warrants issued in the period
|
Fair value of warrants exercised in the period
|
Increase (decrease) in value of warrants
|
Foreign exchange (gain) loss
|
Liability at end of the period
|
|||||||||||||||||||
Three months ended March 31, 2014
|
$ | 5,379 | - | $ | (5,955 | ) | $ | 13,616 | $ | (216 | ) | $ | 12,824 |
March 31, 2014
|
December 31, 2013
|
|||||||
Dividend yield
|
0.00 | % | 0.00 | % | ||||
Expected volatility
|
66.16 | % | 47.03 | % | ||||
Risk-free interest rate
|
1.06 | % | 1.13 | % | ||||
Expected average term (years)
|
1.3
|
1.6
|
||||||
Fair value of warrants outstanding
|
$ | 21.10 | $ | 5.30 | ||||
Aggregate fair value of warrants outstanding
|
$ | 12,824 | $ | 5,379 |
3.
|
Collaborations, contracts and licensing agreements
|
Three months ended March 31
|
||||||||
2014
|
2013
|
|||||||
Collaborations and contracts
|
||||||||
DoD (a)
|
$ | 3,240 | $ | 1,900 | ||||
Monsanto (b)
|
243 | - | ||||||
BMS (d)
|
206 | 232 | ||||||
Total research and development collaborations and contracts
|
3,689 | 2,132 | ||||||
Licensing fees, milestone and royalty payments
|
||||||||
Monsanto licensing fees and milestone payments (b)
|
545 | - | ||||||
Acuitas milestone payments (c)
|
150 | - | ||||||
Spectrum royalty payments (f)
|
46 | - | ||||||
Total licensing fees, milestone and royalty payments
|
741 | |||||||
Total revenue
|
$ | 4,430 | $ | 2,132 |
March 31, 2014
|
December 31, 2013
|
|||||||
DoD (a)
|
$ | 473 | $ | 1,655 | ||||
Monsanto current portion (b)
|
3,594 | - | ||||||
BMS (d)
|
1,534 | 1,808 | ||||||
Other RNAi collaborators (e)
|
20 | - | ||||||
Deferred revenue, current portion
|
5,621 | 3,463 | ||||||
Monsanto long-term portion (b)
|
10,000 | - | ||||||
Total deferred revenue
|
$ | 15,621 | $ | 3,463 |
(a)
|
Contract with United States Government’s Department of Defense (“DoD”) to develop TKM-Ebola
|
(b)
|
Option and Services Agreements with Monsanto Company (“Monsanto”)
|
(c)
|
License and collaboration with Alnylam Pharmaceuticals, Inc. (“Alnylam”) and Acuitas Therapeutics Inc. (“Acuitas”, formerly AlCana Technologies Inc.)
|
(d)
|
Bristol-Myers Squibb (“BMS”) collaboration
|
(e)
|
Other RNAi collaborators
|
(f)
|
Agreements with Spectrum Pharmaceuticals, Inc. (“Spectrum”)
|
(g)
|
License agreement with Merck & Co., Inc. (“Merck”)
|
4.
|
Accounts payable and accrued liabilities
|
March 31, 2014
|
December 31, 2013
|
|||||||
Trade accounts payable
|
$ | 2,141 | $ | 1,217 | ||||
Research and development accruals
|
1,381 | 1,405 | ||||||
Professional fee accruals
|
553 | 247 | ||||||
Deferred lease inducements
|
9 | 16 | ||||||
Other accrued liabilities
|
510 | 795 | ||||||
$ | 4,594 | $ | 3,680 |
5.
|
Financing
|
6.
|
Concentrations of credit risk
|
7.
|
Contingencies and commitments
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | |||||||||||||||||||||||||
2014 | 2013 | 2013 | 2013 | 2013 | 2012 | 2012 | 2012 | |||||||||||||||||||||||||
Revenue
|
||||||||||||||||||||||||||||||||
Collaborations and contracts:
|
||||||||||||||||||||||||||||||||
DoD
|
$ | 3,240 | $ | 2,620 | $ | 2,833 | $ | 2,453 | $ | 1,900 | $ | 3,622 | $ | 1,881 | $ | 2,469 | ||||||||||||||||
Monsanto
|
243 | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Other
|
206 | (131 | ) | 128 | 391 | 232 | 185 | 187 | 174 | |||||||||||||||||||||||
3,689 | 2,489 | 2,961 | 2,844 | 2,132 | 3,807 | 2,068 | 2,643 | |||||||||||||||||||||||||
Monsanto licensing fees and milestone payments
|
545 | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Alnylam milestone payments
|
— | 5,000 | — | — | — | — | — | 1,000 | ||||||||||||||||||||||||
Acuitas milestone payments
|
150 | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Spectrum milestone and royalty payments
|
46 | 40 | 2 | — | — | — | 1,000 | — | ||||||||||||||||||||||||
Total revenue
|
4,430 | 7,527 | 2,963 | 2,844 | 2,132 | 3,807 | 3,068 | 3,643 | ||||||||||||||||||||||||
Expenses
|
(10,388 | ) | (9,962 | ) | (6,615 | ) | (5,915 | ) | (5,126 | ) | (9,816 | ) | (4,824 | ) | (6,206 | ) | ||||||||||||||||
Other income (losses)
|
(12,026 | ) | (162 | ) | (2,254 | ) | 56 | 448 | 44,195 | (1,702 | ) | 627 | ||||||||||||||||||||
Net (loss) income
|
(17,984 | ) | (2,597 | ) | (5,906 | ) | (3,015 | ) | (2,546 | ) | 38,186 | (3,458 | ) | (1,936 | ) | |||||||||||||||||
Basic net (loss) income per share
|
$ | (0.91 | ) | $ | (0.15 | ) | $ | (0.41 | ) | $ | (0.21 | ) | $ | (0.17 | ) | $ | 2.72 | $ | (0.25 | ) | $ | (0.14 | ) | |||||||||
Diluted net (loss) income per share
|
$ | (0.91 | ) | $ | (0.15 | ) | $ | (0.41 | ) | $ | (0.21 | ) | $ | (0.17 | ) | $ | 2.51 | $ | (0.25 | ) | $ | (0.14 | ) |
|
Three months ended March 31,
|
|||||||
2014
|
2013
|
|||||||
Total revenue
|
$ | 4,430 | $ | 2,132 | ||||
Operating expenses
|
10,388 | 5,126 | ||||||
Loss from operations
|
(5,958 | ) | (2,994 | ) | ||||
Net loss
|
(17,984 | ) | (2,546 | ) | ||||
Basic and diluted loss per share
|
(0.91 | ) | (0.18 | ) |
Three months ended March 31, | ||||||||||||||||
2014 | % of Total |
2013
|
% of Total | |||||||||||||
DoD | $ | 3,240 | 73 | % | $ | 1,900 | 89 | % | ||||||||
Monsanto | 243 | 5 | % | - | 0 | % | ||||||||||
BMS | 206 | 5 | % | 232 | 11 | % | ||||||||||
Total collaborations and contracts revenue | 3,689 | 83 | % | 2,132 | 100 | % | ||||||||||
Monsanto licensing fee and milestone payments | 545 | 12 | % | - | 0 | % | ||||||||||
Acuitas milestone payment | 150 | 3 | % | - | 0 | % | ||||||||||
Spectrum milestone and royalty payments | 46 | 1 | % | - | 0 | % | ||||||||||
Total revenue | $ | 4,430 | $ | 2,132 |
Three months ended March 31,
|
||||||||||||||||
2014 | % of Total | 2013 | % of Total | |||||||||||||
Research, development, collaborations and contracts | $ | 8,204 | 79 | % | $ | 4,067 | 79 | % | ||||||||
General and administrative | 2,050 | 20 | % | 893 | 17 | % | ||||||||||
Depreciation | 134 | 1 | % | 166 | 3 | % | ||||||||||
Total operating expenses | $ | 10,388 | $ | 5,126 |
Three months ended March 31, | ||||||||
2014 | 2013 | |||||||
Interest income | $ | 147 | $ | 145 | ||||
Foreign exchange gains (losses) | 1,443 | (5 | ) | |||||
(Increase) decrease in fair value of warrant liability | (13,616 | ) | 308 | |||||
Total other income (losses) | $ | (12,026 | ) | $ | 448 |
Three months ended March 31
|
||||||||
2014
|
2013
|
|||||||
Net income (loss) for the period
|
(17,984 | ) | (2,546 | ) | ||||
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
|
14,879 | (5 | ) | |||||
Changes in operating assets and liabilities
|
12,260 | (289 | ) | |||||
Net cash provided by (used in) operating activities
|
9,155 | (2,840 | ) | |||||
Net cash used in investing activities
|
(335 | ) | (201 | ) | ||||
Net cash provided by financing activities
|
59,289 | 138 | ||||||
Effect of foreign exchange rate changes on cash & cash equivalents
|
(2,469 | ) | (999 | ) | ||||
Net increase (decrease) in cash and cash equivalents
|
65,640 | (3,902 | ) | |||||
Cash and cash equivalents, beginning of period
|
68,717 | 47,024 | ||||||
Cash and cash equivalents, end of period
|
134,357 | 43,122 |
·
|
revenues earned from our Agreements with Monsanto;
|
·
|
revenues earned from our DoD contract to develop TKM-Ebola;
|
·
|
revenues earned from our collaborative partnerships and licensing agreements, including milestone payments from Alnylam and royalties from Spectrum’s sales of Marqibo;
|
·
|
the extent to which we continue the development of our product candidates, add new product candidates to our pipeline, or form collaborative relationships to advance our products;
|
·
|
our decisions to in-license or acquire additional products or technology for development, in particular for our RNAi therapeutics programs;
|
·
|
our ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of our product candidates;
|
·
|
whether batches of drugs that we manufacture fail to meet specifications resulting in delays and investigational and remanufacturing costs;
|
·
|
the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and products;
|
·
|
competing technological and market developments; and
|
·
|
prosecuting and enforcing our patent claims and other intellectual property rights.
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
ITEM 1A.
|
RISK FACTORS
|
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
|
ITEM 3.
|
DEFAULTS UPON SENIOR SECURITIES
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
ITEM 5.
|
OTHER INFORMATION
|
ITEM 6.
|
EXHIBITS
|
10.1
|
Amended Tekmira 2011 Omnibus Share Compensation Plan, as amended on May 8, 2014
|
|
31.1
|
Certification of Chief Executive Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
Certification of Chief Financial Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101
|
Interactive Data Files
|
TEKMIRA PHARMACEUTICALS CORPORATION
|
||
By:
|
/s/ Mark Murray
|
|
Mark Murray
|
||
President and Chief Executive Officer
|
1.
|
PURPOSE OF THE PLAN
|
(a)
|
furnishing certain directors, officers, employees or consultants of the Corporation or an Affiliate or other persons as the Compensation Committee may approve with greater incentive to further develop and promote the business and financial success of the Corporation;
|
(b)
|
furthering the identity of interests of persons to whom equity-based incentive awards may be granted with those of the shareholders of the Corporation generally through share ownership in the Corporation; and
|
(c)
|
assisting the Corporation in attracting, retaining and motivating its directors, officers, employees and consultants.
|
2.
|
DEFINITIONS
|
(a)
|
"Affiliate" means an affiliate company as defined in the Securities Act;
|
(b)
|
“Associate” means an associate as defined in the Securities Act;
|
(c)
|
“Award” means an award of Deferred Stock Units, Options, Restricted Stock Units, or Tandem SARs;
|
(d)
|
“Award Agreement” means an agreement evidencing a Deferred Stock Unit, Option, Restricted Stock Unit or Tandem SAR, entered into by and between the Corporation and an Eligible Person;
|
(e)
|
“Blackout Period” means an interval of time during which trading in securities of the Corporation by officers, directors and employees of the Corporation is prohibited pursuant to the Corporation’s Insider Trading Policy;
|
(f)
|
"Board of Directors" means the board of directors of the Corporation as constituted from time to time;
|
(g)
|
“Change in Control” means:
|
(i)
|
any merger or consolidation in which voting securities of the Corporation possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction and the composition of the Board of Directors following such transaction is such that the directors of the Corporation prior to the transaction constitute less than fifty percent (50%) of the Board of Directors membership following the transaction;
|
(ii)
|
any acquisition, directly or indirectly, by a person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation) of beneficial ownership of voting securities of the Corporation possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities;
|
(iii)
|
any acquisition, directly or indirectly, by a person or related group of persons of the right to appoint a majority of the directors of the Corporation or otherwise directly or indirectly control the management, affairs and business of the Corporation;
|
(iv)
|
any sale, transfer or other disposition of all or substantially all of the assets of the Corporation; and
|
(v)
|
a complete liquidation or dissolution of the Corporation;
|
(h)
|
"Common Shares" means the common shares in the capital of the Corporation as constituted on the Effective Date, provided that if the rights of any Participant are subsequently adjusted pursuant to Article 20 hereof, "Common Shares" thereafter means the shares or other securities or property which such Participant is entitled to purchase after giving effect to such adjustment;
|
(i)
|
"Compensation Committee" has the meaning ascribed thereto in Section 5.1 of this Plan;
|
(j)
|
"Consultant" means any individual, corporation or other person engaged to provide ongoing valuable services to the Corporation or an Affiliate;
|
(k)
|
"Corporation" means Tekmira Pharmaceuticals Corporation and includes any successor corporation thereto;
|
(l)
|
“Deferred Stock Unit” means a right granted to an Eligible Person in accordance with Section 11 to receive, on a deferred payment basis, a cash payment or Common Shares, or any combination thereof, as determined by the Compensation Committee and on the terms contained in this Plan;
|
(m)
|
"Effective Date" has the meaning ascribed thereto by Section 3.1 of this Plan;
|
(n)
|
"Eligible Person" means a director, officer, employee or Consultant of the Corporation or an Affiliate or a person otherwise approved by the Compensation Committee;
|
(o)
|
"Exercise Price" means the price per Common Share at which a Participant may purchase Common Shares pursuant to an Option, provided that if such price is adjusted pursuant to Section 20.1 hereof, "Exercise Price" thereafter means the price per Common Share at which such Participant may purchase Common Shares pursuant to such Option after giving effect to such adjustment;
|
(p)
|
“Fair Market Value” as it relates to Common Shares means:
|
(i)
|
where the Common Shares are listed for trading on a Stock Exchange, the closing price of the Common Shares on such Stock Exchange as determined by the Compensation Committee, for the Trading Session on the day prior to the relevant time as it relates to an Award; or
|
(ii)
|
where the Common Shares are not publicly traded, the value which is determined by the Compensation Committee to be the fair value of the Common Shares at the relevant time as it relates to an Award, taking into consideration all factors that the Compensation Committee deems appropriate, including, without limitation, recent sale and offer prices of the Common Shares in private transactions negotiated at arm’s length;
|
(q)
|
“Insider” means:
|
(i)
|
an insider as defined in the Securities Act; and
|
(ii)
|
an Associate or Affiliate of any person who is an insider;
|
(r)
|
“Key Employee” means an employee of the Corporation who at any time during the calendar year is an officer of the Corporation whose annual compensation is equal to or greater than US$130,000, an employee whose share ownership in the Corporation is 5% or more, or an employee whose share ownership in the Corporation is 1% or more and whose annual compensation exceeds US$150,000, or as U.S. federal tax law is amended in this regard from time to time;
|
(s)
|
"Legal Representative" has the meaning ascribed thereto by Section 14.1 of this Plan;
|
(t)
|
“Merger and Acquisition Transaction” means:
|
(i)
|
any merger;
|
(ii)
|
any acquisition;
|
(iii)
|
any amalgamation;
|
(iv)
|
any offer for shares of the Corporation which if successful would entitle the offeror to acquire all of the voting securities of the Corporation; or
|
(v)
|
any arrangement or other scheme of reorganization;
|
(u)
|
“Non Blackout Trading Day” means a day on which (i) a Trading Session occurs, and (ii) no Blackout Period is in place;
|
(v)
|
“Notice of Settlement” means a notice delivered to the Corporation in the form prescribed by the Corporation from time to time, or in absence of such form, a written notice indicating the Participant’s desire to receive his or her Settlement Amount and delivered to the Corporation;
|
(w)
|
"Options" means stock options granted hereunder to purchase Common Shares from treasury pursuant to the terms and conditions hereof and as evidenced by an Option Agreement and “Option” means any one of them;
|
(x)
|
"Option Agreement" means an agreement evidencing an Option, entered into by and between the Corporation and an Eligible Person;
|
(y)
|
"Outstanding Common Shares" at the time of any share issuance or grant of Options means the number of Common Shares that are outstanding immediately prior to the share issuance or grant of Options in question, on a non-diluted basis, or such other number as may be determined under the applicable rules and regulations of all regulatory authorities to which the Corporation is subject, including the Stock Exchange;
|
(z)
|
"Participant" means a person to whom an Award has been granted under this Plan;
|
(aa)
|
"Plan" means the Tekmira 2011 Omnibus Share Compensation Plan, as the same may from time to time be supplemented or amended and in effect;
|
(bb)
|
“Restricted Stock Unit” means a right granted to an Eligible Person in accordance with Section 10 to receive a cash payment or Common Shares, or a combination thereof, as determined by the Compensation Committee, equal in value to the Fair Market Value of the Common Shares on an applicable future settlement date as specified by the Compensation Committee, on the terms and conditions and calculated in accordance with Section 10 hereof;
|
(cc)
|
“Settlement Amount” means an amount paid to the holder of Deferred Stock Units as determined pursuant to Section 11;
|
(dd)
|
“Securities Act” means the Securities Act, R.S.B.C. 1996, c.418, as amended from time to time;
|
(ee)
|
"Stock Exchange" means such stock exchange or other organized market on which the Common Shares are listed or posted for trading;
|
(ff)
|
“Tandem SAR” means a right, granted in accordance with Section 9 in tandem with an Option, to receive upon the exercise thereof payment in cash, Common Shares or any combination thereof, as determined by the Compensation Committee, an amount equal to the excess of the Fair Market Value of the Common Shares on the date of exercise of such Tandem SAR over the Option Exercise Price, on the terms and conditions and calculated in accordance with Section 9 hereof;
|
(gg)
|
“Terminated Service” means that a Participant has, except as a result of death or disability, ceased to be a director, officer, employee or Consultant of the Corporation, as the case may be;
|
(hh)
|
“Trading Session” means a trading session on a day which the applicable Stock Exchange is open for trading;
|
(ii)
|
"U.S. Exchange Act" means the U.S. Securities Exchange Act of 1934, as amended from time to time;
|
(jj)
|
“U.S. Internal Revenue Code” means the Internal Revenue Code of 1986 of the United States, as amended from time to time;
|
(kk)
|
"U.S. Nonqualified Stock Option" means an Option to purchase Common Shares other than a U.S. Qualified Incentive Stock Option;
|
(ll)
|
“U.S. Optionee” or “U.S. Person” means a Participant who is a citizen or a resident of the United States (including its territories, possessions and all areas subject to the jurisdiction); and
|
(mm)
|
"U.S. Qualified Incentive Stock Option" means an Option to purchase Common Shares with the intention that it qualify as an "incentive stock option" as that term is defined in Section 422 of the U.S. Internal Revenue Code, such intention being evidenced by the resolutions of the Compensation Committee at the time of grant.
|
3.
|
EFFECTIVE DATE OF PLAN
|
4.
|
COMMON SHARES SUBJECT TO PLAN
|
5.
|
ADMINISTRATION OF PLAN
|
(a)
|
to interpret and construe this Plan and any Award Agreement and to determine all questions arising out of this Plan and any Award Agreement, and any such interpretation, construction or determination made by the Compensation Committee will be final, binding and conclusive for all purposes;
|
(b)
|
to determine to which Eligible Persons Awards are granted, and to grant, Awards;
|
(c)
|
to determine the number of Common Shares issuable pursuant to each Award;
|
(d)
|
to determine the Exercise Price for each Option;
|
(e)
|
to determine the time or times when Awards will be granted, vest and be exerciseable, as applicable;
|
(f)
|
to determine the vesting terms of Awards, which may be based upon the passage of time, continued employment or service, on the basis of corporate or personal performance objectives, or any combination of the foregoing as determined by the Compensation Committee;
|
(g)
|
to determine any acceleration of vesting;
|
(h)
|
to determine if the Common Shares that are subject to an Award will be subject to any restrictions or repurchase rights upon the exercise or settlement of such Award including, where applicable, the endorsement of a legend on any certificate representing Common Shares acquired on the exercise or settlement of any Award to the effect that such Common Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada, the United States or any other country and if any rights or restrictions exist they will be described in the applicable Award Agreement;
|
(i)
|
to determine the expiration date for each Award and to extend the period of time for which any Award is to remain exerciseable or may be settled in appropriate circumstances, including, without limitation, in the event of the Participant's cessation of employment or service, provided that such date may not be later than the earlier of (A) the latest date permitted under the applicable rules and regulations of all regulatory authorities to which the Corporation is subject, including the Stock Exchange, and (B) in the case of an Option and, if applicable, Tandem SAR, the date which is the tenth anniversary of the date on which such Option and, if applicable, Tandem SAR is granted;
|
(j)
|
to prescribe the form of the instruments relating to the grant, exercise, or settlement, as applicable, and other terms of Awards;
|
(k)
|
to enter into an Award Agreement evidencing each Award which will incorporate such terms as the Compensation Committee in its discretion deems consistent with this Plan;
|
(l)
|
to take such steps and require such documentation from Eligible Persons which in its opinion are necessary or desirable to ensure compliance with the rules and regulations of the Stock Exchange and all applicable laws;
|
(m)
|
to adopt such modifications, procedures and subplans as may be necessary or desirable to comply with the provisions of the laws of Canada, the United States and other countries in which the Corporation or its Affiliates may operate to ensure the viability and maximization of the benefits from the Awards granted to Participants residing in such countries and to meet the objectives of this Plan; and
|
(n)
|
to determine such other matters as provided for herein.
|
6.
|
GRANT OF OPTIONS
|
(a)
|
the number of Common Shares reserved for issuance to any one Participant pursuant to this Plan within any one year period shall not, in aggregate, exceed 5% of the total number of Outstanding Common Shares on a non-diluted basis; and
|
(b)
|
the number of Common Shares:
|
(i)
|
issuable, at any time, to Participants that are Insiders; and
|
(ii)
|
issued to Participants that are Insiders within any one year period;
|
7.
|
U.S. QUALIFIED INCENTIVE STOCK OPTION PROVISIONS
|
(i)
|
the Exercise Price (per Common Share) subject to such U.S. Qualified Incentive Stock Option shall not be less than one hundred ten percent (110%) of the fair market value of one Common Share at the time of grant; and
|
(ii)
|
for the purposes of this Article 7 only, the option exercise period shall not exceed five (5) years from the date of grant.
|
8.
|
EXERCISE OF OPTIONS
|
(a)
|
cash, bank draft or certified cheque; or
|
(b)
|
such other consideration as the Compensation Committee may permit consistent with applicable laws.
|
(a)
|
completion of such registration or other qualification of such Common Shares or obtaining approval of such governmental authority as the Corporation will determine to be necessary or advisable in connection with the authorization, issuance or sale thereof;
|
(b)
|
the admission of such Common Shares to listing or quotation on the Stock Exchange; and
|
(c)
|
the receipt from the Participant of such representations, agreements and undertakings, including as to future dealings in such Common Shares, as the Corporation or its counsel determines to be necessary or advisable in order to safeguard against the violation of the securities laws of any jurisdiction.
|
9.
|
GRANT OF TANDEM SARS
|
(a)
|
made in Common Shares shall be equal to such number of Common Shares having an aggregate value equal to the excess of the Fair Market Value of a Common Share on the date of exercise of the Tandem SAR over the Option Exercise Price for the corresponding Option, multiplied by the number of Tandem SARs exercised;
|
(b)
|
made by a cash payment shall be an aggregate amount equivalent to the value derived by 9.4(a); and
|
(c)
|
made by a combination of a cash payment and Common Shares shall be equivalent to the value derived by 9.4(a).
|
10.
|
GRANT OF RESTRICTED STOCK UNITS
|
(a)
|
made in Common Shares shall be made by delivery of one Common Share for each such Restricted Stock Unit then being settled;
|
(b)
|
made by a cash payment shall be an aggregate amount equal to the product of the Fair Market Value of the Common Shares on the applicable settlement date as specified by the Compensation Committee, multiplied by the number of Restricted Stock Units then being settled; and
|
(c)
|
made by a combination of a cash payment and Common Shares shall be equivalent to the value derived by 10.3(b).
|
11.
|
GRANT OF DEFERRED STOCK UNITS
|
(a)
|
made in Common Shares shall be made by delivery of one Common Share for each such Deferred Stock Unit then being settled on the Filing Date;
|
(b)
|
made by a cash payment shall be an aggregate amount equivalent to the value derived by 11.4(a); and
|
(c)
|
made by a combination of a cash payment and Common Shares will be equivalent to the value derived by 11.4(a).
|
(a)
|
Non-U.S. Persons
|
(i)
|
a Participant who is not a U.S. Person and who has Terminated Service may receive their Settlement Amount by filing a Notice of Settlement on or before December 15 of the first calendar year commencing after the date of the Participant’s Terminated Service. If the Participant fails to file such notice on or before that December 15, the Participant will be deemed to have filed the Notice of Settlement on that December 15.
|
(ii)
|
subject to Article 18 herein, the Corporation shall make payment of the Settlement Amount as soon as reasonably possible following the Filing Date.
|
(iii)
|
in the event of the death of a Participant who is not a U.S. Person, the Corporation will, subject to Article 18 herein, make payment of the Settlement Amount within two months of the Participant’s death to or for the benefit of the legal representative of the deceased Participant. For the purposes of this subsection, the Filing Date shall be the date of the Participant’s death.
|
(iv)
|
if a Participant who is not a U.S. Person dies after the Participant has Terminated Service but before filing a Notice of Settlement, Section 11.5(a)(iii) will apply.
|
(b)
|
U.S. Persons
|
(i)
|
in the event that a Participant who is a U.S. Person and not a Key Employee has Terminated Service, the Corporation will, subject to Article 18 herein, make payment of the Settlement Amount as soon as reasonably possible following such Participant’s Terminated Service. For the purposes of this subsection, the Filing Date shall be the date that such Participant Terminated Service.
|
(ii)
|
in the event that a Participant who is a U.S. Person and a Key Employee has Terminated Service, the Corporation will, subject to Article 18 herein, make payment of the Settlement Amount as soon as is reasonably possible following the date that is 6 months after the date that such Participant Terminated Service. For the purposes of this subsection, the Filing Date shall be the date which is 6 months after the date that such Participant Terminated Service. In the event of death of such a Participant during the 6 month period following the date the Participant Terminated Service, the rules under Section 11.5(b)(ii) shall then apply.
|
(iii)
|
in the event of the death of a Participant who is a U.S. Person, the Corporation will, subject to Article 18 herein, make payment of the Settlement Amount within two months of the Participant’s death to or for the benefit of the legal representative of the deceased Participant. For the purposes of this subsection, the Filing Date shall be the date of the Participant’s death.
|
12.
|
TERM OF AWARDS
|
(a)
|
the date determined by the Compensation Committee and specified in the Award Agreement pursuant to which such Option and, if applicable, Tandem SAR is granted, provided that such date may not be, subject to Article 18 later than the earlier of (A) the date which is the tenth anniversary of the date on which such Option and, if applicable, Tandem SAR is granted, and (B) the latest date permitted under the applicable rules and regulations of all regulatory authorities to which the Corporation is subject, including the Stock Exchange;
|
(b)
|
in the event the Participant ceases to be an Eligible Person for any reason, other than the death of the Participant or the termination of the Participant for cause, such period of time after the date on which the Participant ceases to be an Eligible Person as may be specified by the Compensation Committee or as specified in an agreement among the Participant and the Corporation, and in the absence of such specification or agreement, will be deemed to be the date that is three months following the Participant ceasing to be an Eligible Person
|
(c)
|
in the event of the termination of the Participant as a director, officer, employee or Consultant of the Corporation or an Affiliate for cause, the date of such termination;
|
(d)
|
in the event of the death of a Participant prior to: (A) the Participant ceasing to be an Eligible Person; or (B) the date which is the number of days specified by the Compensation Committee pursuant to subparagraph (b) above from the date on which the Participant ceased to be an Eligible Person; the date which is one year after the date of death of such Participant or such other date as may be specified by the Compensation Committee and which period will be specified in the Award Agreement with the Participant with respect to such Option ; and
|
(e)
|
notwithstanding the foregoing provisions of subparagraphs (b), (c) and (d) of this Section 12.1, the Compensation Committee may, subject Article 19 and to regulatory approval, at any time prior to expiry of an Option extend the period of time within which an Option may be exercised by a Participant who has ceased to be an Eligible Person, but such an extension shall not be granted beyond the original expiry date of the Option as provided for in subparagraph (a) above.
|
(a)
|
in the event a Participant ceases to be an Eligible Person due to death or retirement, any then outstanding Restricted Stock Units that have not become vested and settled prior to the Participant ceasing to be an Eligible Person shall immediately vest and be settled as soon as reasonably practicable after the date that such Participant ceases to be an Eligible Person;
|
(b)
|
in the event a Participant ceases to be an Eligible Person due to resignation, any then outstanding Restricted Stock Units that have not become vested and settled prior to the Participant ceasing to be an Eligible Person shall immediately be forfeited and cancelled; and
|
(c)
|
in the event a Participant ceases to be an Eligible Person due to disability or termination without cause, any then outstanding Restricted Stock Units that have not become vested and settled prior to the Participant ceasing to be an Eligible Person shall vest and be settled at the discretion of the Compensation Committee.
|
13.
|
CHANGE IN STATUS
|
14.
|
NON-TRANSFERABILITY OF AWARDS
|
15.
|
REPRESENTATIONS AND COVENANTS OF PARTICIPANTS
|
(a)
|
the Participant is a director, officer, employee, or Consultant of the Corporation or an Affiliate or a person otherwise approved as an "Eligible Person" under this Plan by the Compensation Committee;
|
(b)
|
the Participant has not been induced to enter into such Award Agreement by the expectation of employment or continued employment with the Corporation or an Affiliate;
|
(c)
|
the Participant is aware that the grant of the Award and the issuance by the Corporation of Common Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document qualifying the distribution of the Awards or the Common Shares to be distributed thereunder under any applicable securities laws;
|
(d)
|
upon each exercise or settlement of an Award, the Participant, or the Legal Representative of the Participant, as the case may be, will, if requested by the Corporation, represent and agree in writing that the person is, or the Participant was, a director, officer, employee or Consultant of the Corporation or an Affiliate or a person otherwise approved as an "Eligible Person" under this Plan by the Compensation Committee and has not been induced to purchase the Common Shares by expectation of employment or continued employment with the Corporation or an Affiliate, and that such person is not aware of any commission or other remuneration having been paid or given to others in respect of the trade in the Common Shares; and
|
(e)
|
if the Participant or the Legal Representative of the Participant exercises or settles the Award, the Participant or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares received pursuant to the exercise or settlement of the Award, comply with all applicable securities laws and all applicable rules and regulations of all regulatory authorities to which the Corporation is subject, including the Stock Exchange, and will not offer, sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any Corporation, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the securities laws of the United States.
|
16.
|
PROVISIONS RELATED TO SHARE ISSUANCES
|
17.
|
WITHHOLDING TAX
|
18.
|
EXERCISE AND SETTLEMENT OF AWARDS DURING BLACKOUT PERIODS
|
19.
|
SUSPENSION, AMENDMENT OR TERMINATION OF PLAN
|
(a)
|
with approval of shareholders of the Corporation by ordinary resolution make any amendment to any Award Agreement or the Plan; and
|
(b)
|
without approval of shareholders of the Corporation make the following amendments to any Award Agreement or the Plan:
|
(i)
|
amendments of a clerical nature, including but not limited to the correction of grammatical or typographical errors or clarification of terms;
|
(ii)
|
amendments to reflect any requirements of any regulatory authorities to which the Corporation is subject, including the Stock Exchange;
|
(iii)
|
subject to the terms and conditions of the Plan, amendments to vesting provisions of Award Agreements;
|
(iv)
|
extend the term of Options and Tandem SARs held by non-Insiders of the Corporation;
|
(v)
|
reduce the Exercise Price per Common Share under any Option held by non-Insiders of the Corporation or replace such Option with a lower Exercise Price per Common Share under such replacement Option; and
|
(vi)
|
amendments which provide cashless exercise features to an Option that require the full deduction of the number of underlying Common Shares from the total number of Common Shares subject to the Plan.
|
(a)
|
without the prior approval of shareholders and except as permitted pursuant to Article 20, (i) extend the term of an Option or Tandem SAR held by an Insider of the Corporation; or (ii) reduce the Exercise Price per Common Share under any Option held by an Insider of the Corporation; or (iii) cancel any Option held by an Insider and replace such Option within three months;
|
(b)
|
affect in a manner that is adverse or prejudicial to, or that impairs, the benefits and rights of any Participant under any Award previously granted under this Plan (except as permitted pursuant to Article 20 and except for the purpose of complying with applicable securities laws or the bylaws, rules and regulations of any regulatory authority to which the Corporation is subject, including the Stock Exchange);
|
(c)
|
decrease the number of Common Shares which may be purchased pursuant to any Option (except as permitted pursuant to Article 20) without the consent of such Participant;
|
(d)
|
set the Exercise Price of any Option below the Fair Market Value of such Option on the date of grant;
|
(e)
|
increase the Exercise Price at which Common Shares may be purchased pursuant to any Option (except as permitted pursuant to Article 20) without the consent of such Participant;
|
(f)
|
extend the term of any Option beyond a period of ten years or the latest date permitted under the applicable rules and regulations of all regulatory authorities to which the Corporation is subject, including the Stock Exchange;
|
(g)
|
grant any Award if this Plan is suspended or has been terminated; or
|
(h)
|
change or adjust any outstanding U.S. Qualified Incentive Stock Option without the consent of the Participant if such change or adjustment would constitute a "modification" that would cause such U.S. Qualified Incentive Stock Option to fail to continue to qualify as a U.S. Qualified Incentive Stock Option.
|
20.
|
ADJUSTMENTS
|
(a)
|
the Compensation Committee may, in a fair and equitable manner, determine the manner in which all unexercised Options or unsettled Awards granted under this Plan will be treated including, without limitation, requiring the acceleration of the time for the exercise or settlement of Awards by the Participants, the time for the fulfilment of any conditions or restrictions on such exercise or settlement, and the time for the expiry of such rights; or
|
(b)
|
the Compensation Committee or any corporation which is or would be the successor to the Corporation or which may issue securities in exchange for Common Shares upon the Merger and Acquisition Transaction becoming effective may offer any Participant the opportunity to obtain a new or replacement awards over any securities into which the Common Shares are changed or are convertible or exchangeable, on a basis proportionate to the number of Common Shares under Award, including Exercise Price, as applicable (and otherwise substantially upon the terms of the Award being replaced, or upon terms no less favourable to the Participant) including, without limitation, the periods during which the Award may be exercised or settled and expiry dates of such Awards; and in such event, the Participant shall, if he accepts such offer, be deemed to have released his Award over the Common Shares and such Award shall be deemed to have lapsed and be cancelled; or
|
(c)
|
the Compensation Committee may commute for or into any other security or any other property or cash, any Award that is still capable of being exercised or settled, upon giving to the Participant to whom such Award has been granted at least 30 days written notice of its intention to commute such Award, and during such period of notice, the Award, to the extent it has not been exercised or settled, may be exercised or settled by the Participant without regard to any vesting conditions attached thereto; and on the expiry of such period of notice, the unexercised or unsettled portion of the Award shall lapse and be cancelled.
|
21.
|
GENERAL
|
1.
|
I have reviewed this Form 10-Q Tekmira Pharmaceuticals Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Mark Murray
|
||
Name:
|
Mark Murray
|
|
Title:
|
President and Chief Executive Officer
|
1.
|
I have reviewed this Form 10-Q of Tekmira Pharmaceuticals Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Bruce Cousins
|
||
Name:
|
Bruce Cousins
|
|
Title:
|
Executive Vice President, Finance and
Chief Financial Officer
|
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.
|
/s/ Mark Murray
|
||
Name:
|
Mark Murray
|
|
< |